|Dr. Albert David Friesen Ph.D.||Founder, Chairman, Pres & Chief Exec. Officer||N/A||N/A||70|
|Mr. James F. Kinley C.A.||CFO & Sec.||114.69k||N/A||39|
|Mr. Graeme William Merchant B.B.A.||VP of Commercial Operations||146.67k||237.41k||N/A|
|Dr. George Roby Thomas M.Pharm, Ph.D.||Director of R&D||N/A||N/A||N/A|
Medicure Inc., a specialty pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, Barbados, and India. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome. It is also developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications. In addition, the company manufactures, develops, markets, and sells active pharmaceutical ingredients to generic pharmaceutical customers; and provides customs synthesis for early phase pharmaceutical research of branded products, as well as participates in collaborations with other parties in the research and development stages of specific products. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.
Medicure Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.